Know Cancer

or
forgot password

The Effect and Mechanism of Improving Diabetes by Reconstruction Methods in Gastric Cancer Patients With DM Who Receive Surgical Treatment


N/A
20 Years
80 Years
Open (Enrolling)
Both
Gastric Cancer, Diabetes

Thank you

Trial Information

The Effect and Mechanism of Improving Diabetes by Reconstruction Methods in Gastric Cancer Patients With DM Who Receive Surgical Treatment


Purpose:

- To investigate the effect of gastrectomy on remission of type 2 diabetes in patients
with gastric cancer and type 2 diabetes

- To investigate the mechanism of blood glucose alteration and intestinal hormonal
signaling by the reconstruction methods

- To evaluate the applicability and efficacy of Roux-en-Y gastrojejunostomy after
gastrectomy in gastric cancer patients with diabetes

Contents:

- Evaluation of the status of diabetes in gastric cancer patients with DM after
gastrectomy

- Comparison of two reconstruction types after gastrectomy Bypass duodenum and upper
jejunum: Roux-en-Y gastrojejunostomy Preservation of duodenal passage:
Gastroduodenostomy

- Analysis for biochemical markers reflecting diabetic status: fasting glucose,
postprandial 2h glucose, HbA1c, C-peptide, lipid profile

- Correlation of parameters associated with diabetes and GI hormones

- Measurement of GI hormones which have an effect on glucose tolerance

- Insulin, glucagon, IGF-1, GLP-1, Neuropeptide Y, Ghrelin, Leptin

- Correlation of reconstruction methods, parameters of diabetes and GI hormone
levels

- Evaluation of mechanism of Roux-en-Y gastrojejunostomy on controlling diabetes

- Evaluation of Feasibility of Roux-en-Y gastrojejunostomy in gastric cancer surgery in
patients with DM

- Degree of high blood glucose control, the amount of antidiabetic medication, costs
for DM treatment, quality of life assessment

- Analysis for the mechanism of gastrointestinal physiology to diabetes control


Inclusion Criteria:



- Patient who are older than 20 years and younger than 80 years

- Histologically confirmed gastric adenocarcinoma located lower one third of stomach

- Postoperative confirmed pT1N0, pT2N0, pT1N1

- Informed consent

Exclusion Criteria:

- Previous history of treatment for other malignancy or inflammatory disease

- Preoperative uncontrolled serious comorbidity

- Vulnerable Subjects(pregnant women, children, cognitively impaired persons etc.)

- Patient who experience any complications requiring reoperation following gastrectomy

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Blood sugar stabilization after gastrectomy

Outcome Description:

By comparing the difference between fasting blood sugar and postprandial blood glucose, blood sugar stabilization after gastrectomy will be maesured.

Outcome Time Frame:

three months after surgery

Safety Issue:

No

Authority:

South Korea: Korea Food and Drug Administration (KFDA)

Study ID:

4-2011-0109

NCT ID:

NCT01375738

Start Date:

July 2011

Completion Date:

May 2014

Related Keywords:

  • Gastric Cancer
  • Diabetes
  • Early gastric cancer
  • Diabetes Mellitus
  • Stomach Neoplasms

Name

Location